We claim

1. Use of a composition in the manufacture of a medicament for treating a lung tumor, wherein the use comprises that an amount effective of the composition comprising taxane particles to treat the lung tumor is to be pulmonary administered to the subject, wherein the taxane particles comprise at least 95% of the taxane and have a mean particle size (number) of between 0.1 μm and 5 μm, wherein the taxane particles have a specific surface area (SSA) of at least 12 m2/g, wherein the taxane particles are present in a suspension comprising the taxane particles and a pharmaceutically acceptable carrier, wherein the suspension is aerosolized for administration, wherein the pulmonary administration comprises nebulization, and wherein the nebulization results in pulmonary delivery to the subject of aerosol droplets of the taxane particles suspension.

2. The use of claim 1, wherein the taxane particles have a mean particle size (number) of between 0.4 μm and 3 μm.

3. The use of any one of claims 1-2, wherein the taxane particles have a mean particle size (number) of between 0.4 μm and 1.2 μm.

4. The use of any one of claims 1-3, wherein the taxane particles have a specific surface area (SSA) of at least 18 m^2/g.

5. The use of any one of claims 1-4, wherein the suspension further comprises a polysorbate, wherein the polysorbate is present in the suspension at a concentration of between 0.01% v/v and 1.5% v/v.

6. The use of claim 5, wherein the pharmaceutically acceptable carrier is saline.

7. The use of claim 5 or 6, wherein the polysorbate is polysorbate 80.

8. The use of any one of claims 5-7, wherein the taxane is present in the suspension at a concentration between 1 mg/ml and 40 mg/ml.

9. The use of any one of claims 1-8, wherein the taxane particles are uncoated and exclude lipids, polymers, proteins, polyethoxylated castor oil, and polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol.

10. The use of any one of claims 1-9, wherein the taxane comprises paclitaxel, docetaxel, cabazitaxel, or a pharmaceutically acceptable salt thereof.

11. The use of claim 10, wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

12. The use of claim 1, wherein the taxane particles have a mean bulk density between 0.050 g/cm^3 and 0.12 g/cm^3.

13. The use of claim 10, wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

14. The use of any one of claims 1-13, wherein the taxane remains detectable in lung tissue of the subject for at least 4 days after administration.

15. The use of any one of claims 1-14, wherein the taxane particles are in crystalline form.

16. The use of any one of claims 1-15, wherein the aerosol droplets have a mass median aerodynamic diameter (MMAD) of between 0.5 μm to 6 μm diameter.

17. The use of any one of claims 1-16, wherein the taxane particles reside at the tumor site after administration of the composition exposing the tumor to the taxane particles for a sustained amount of time sufficient to stimulate the endogenous immune system of the subject resulting in the production of tumoricidal cells and infiltration of the tumoricidal cells into the tumor at a level sufficient to treat the tumor.

18. The use of claim 17, wherein the sustained amount of time is at least 4 weeks.

19. The use of any one of claims 17-18, wherein the tumoricidal cells comprise T-cells, B cells, or natural killer (NK) cells, or combinations thereof.

20. The use of any one of claims 1-19, wherein the composition is to be administered in two or more separate administrations.

21. The use of claim 20, wherein the composition is to be administered once a week for at least two weeks.

22. The use of claim 20, wherein the composition is to be administered twice a week for at least one week, wherein the two or more separate administrations are separated by at least one day.

23. The use of any one of claims 1-22, wherein the treatment of the tumor is elimination of the tumor.